Category - Developments

Developments

iBio to be added to Russell 2000 and Russell 3000 indexes

iBio (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes after markets open on June 29, as part of the Russell indexes annual reconstitution. In early trading on June 26, shares of iBio...

June 26, 2020

Developments

Imara granted FDA orphan drug designation for the treatment of beta-thalassemia

The FDA granted Imara’s (NASDAQ:IMRA) IMR-687 orphan drug designation for the treatment of beta-thalassemia. Beta-thalassemia is a blood disorder characterized by reduced levels of hemoglobin. IMR-687 is small molecule...

June 24, 2020

Developments

Titan Pharma and Indegene sign Probuphine co-promotion partnership

Titan Pharmaceuticals (NASDAQ:TTNP) signed a co-promotion partnership with Indegene to establish multichannel digital marketing programs across the U.S. and engage health care providers (HCPs) who are eligible to...

June 24, 2020

Developments

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

IBM Watson Health selected iBio (NYSE American:IBIO) to receive 18 months use of the IBM clinical development (ICD) solution at no cost. IBM Watson Health recently began offering its clinical development solution to...

June 24, 2020

Developments

Kane Biotech receives new funding from CanExport SMEs program

Kane Biotech (TSX-V:KNE; OTCQB:KNIBF) has been approved for up to $54,750 in funding from the Government of Canada’s CanExport small and medium-sized enterprises (SMEs) program. The program provides direct...

June 24, 2020

Developments

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 demonstrated antifibrotic activity in an experimental model of renal fibrosis. The study, which was conducted by SMC Laboratories in Tokyo, Japan, evaluated CRV431 in the...

June 22, 2020

Developments

Ziopharm completes enrollment of Phase 2 glioblastoma trial

Ziopharm Oncology (NASDAQ:ZIOP) completed enrollment of 36 subjects in its Phase 2 trial evaluating controlled IL-12, in combination with PD-1 inhibitor cemiplimab, for the treatment of recurrent or progressive...

June 22, 2020

Developments

Stereotaxis to be added to the Russell 2000 and Russell 3000 indexes

Stereotaxis (NYSE: STXS) will be added to the Russell 2000 and Russell 3000 indexes after the close on June 26, as part of the Russell indexes annual reconstitution. “This is another step forward in our effort to...

June 22, 2020

Developments

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

uniQure (NASDAQ:QURE) dosed the first two patients in its Phase 1/2 trial evaluating AMT-130 for the treatment of Huntington’s disease (HD). HD is an inherited neurodegenerative disorder where production and aggregation...

June 19, 2020

Developments

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Ovid Therapeutics’ (NASDAQ:OVID) OV101 received FDA rare pediatric disease designation for the treatment of Angelman syndrome. Angelman syndrome is a rare genetic disorder that affects the brain’s ability to correctly...

June 19, 2020

Category - Developments

iBio to be added to Russell 2000 and Russell 3000 indexes

Imara granted FDA orphan drug designation for the treatment of beta-thalassemia

Titan Pharma and Indegene sign Probuphine co-promotion partnership

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

Kane Biotech receives new funding from CanExport SMEs program

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Ziopharm completes enrollment of Phase 2 glioblastoma trial

Stereotaxis to be added to the Russell 2000 and Russell 3000 indexes

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter